Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Stock Yards Bancorp (NASDAQ: SYBT) Executive Owned 1,039 Shares After Forfeiture

Stock Yards Bancorp, Inc. (NASDAQ: SYBT) senior vice president Michael W. Woods forfeited 61 shares at $80.28 per share. The share forfeiture was dated September 3, 2026.

Vinay Lochav | 08 September 2026

Virax Biolabs (NASDAQ: VRAX) Raises ATM Offering Capacity to $2.07M

Virax Biolabs Group Ltd (NASDAQ: VRAX) increased the maximum aggregate value of ordinary shares available for sale under its At The Market Offering Agreement to $2,070,060.20.

Vinay Lochav | 08 September 2026

Perspective Therapeutics (AMEX: CATX) Owner Sells 113,914 Shares at Up to $3.14

Perspective Therapeutics, Inc. (AMEX: CATX) 10% owner Lantheus Alpha Therapy, LLC sold 113,914 shares at prices ranging from $3.12 to $3.14 per share. The sales occurred across two transactions between August 31 and September 1, 2026.

Vinay Lochav | 08 September 2026

Protalix BioTherapeutics (AMEX: PLX) CEO Reports 160,000 Derivative Securities After Award

Protalix BioTherapeutics, Inc. (AMEX: PLX) awarded 480,000 derivative securities to Bashan Dror, its president and CEO. The transactions were dated 3 September 2026 and carried a stated price of $0 per share.

Vinay Lochav | 08 September 2026

Protalix BioTherapeutics Executive Awarded 168,000 Derivative Securities (AMEX: PLX)

Protalix BioTherapeutics, Inc. (AMEX: PLX) awarded Naos Yaron 168,000 derivative securities across two transactions. The transactions took place on 3 September 2026 at $0 per share.

Vinay Lochav | 08 September 2026

Protalix BioTherapeutics (AMEX: PLX) Reports September 3 Insider Securities Award

Protalix BioTherapeutics, Inc. (AMEX: PLX) awarded Bar-Shalev Amos 25,500 derivative securities across two transactions, with each transaction priced at $0 per share. Amos is identified as an insider of Protalix BioTherapeutics. The two transactions were dated 3 September 2026.

Vinay Lochav | 08 September 2026

Rein Therapeutics (NASDAQ: RNTX) Advances LTI-03 Into Phase 2 Trial

Rein Therapeutics, Inc. (NASDAQ: RNTX) is advancing LTI-03 into a Phase 2 trial for idiopathic pulmonary fibrosis, with the RENEW study now enrolling. The candidate is positioned as a potential treatment for a fatal disease marked by progressive lung scarring.

Vinay Lochav | 08 September 2026

VERACYTE, INC. Forfeits 3,961 Shares at $44.88 (NASDAQ: VCYT)

VERACYTE, INC. (NASDAQ: VCYT) recorded the forfeiture of 3,961 shares tied to executive Leite John. The transaction took place on Sep. 2, 2026, and left John with 128,344 shares.

Vinay Lochav | 08 September 2026

Veracyte (NASDAQ: VCYT) General Counsel Forfeits 3,215 Shares at $44.88

VERACYTE, INC. (NASDAQ: VCYT) executive Annie McGuire forfeited 3,215 shares at $44.88 per share. McGuire is the company’s executive vice president and general counsel, and the forfeiture occurred on September 2, 2026.

Vinay Lochav | 08 September 2026

VERACYTE CEO Forfeits 8,782 Shares at $44.88 (NASDAQ: VCYT)

VERACYTE, INC. (NASDAQ: VCYT) said Chief Executive Officer Marc Stapley forfeited 8,782 shares at $44.88 per share. The transaction was recorded on September 2, 2026, and left Stapley with 432,073 shares. The filing reported Stapley’s forfeiture of 8,782 Veracyte shares at $44.88 per share. …

Vinay Lochav | 08 September 2026
Support

Hi! How can we help you today?

Loading…